Large granular lymphocytes in metastatic non-small cell lung cancer treated with nivolumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study measuring large granular lymphocytes (LGLs) by peripheral blood smear in patients with metastatic non-small cell lung cancer treated with nivolumab as second-line therapy. LGL percentage will be recorded at baseline and at three months and correlated with treatment response and clinical parameters. Eligible participants have histologically confirmed metastatic NSCLC, ECOG 0–2, and no recent steroids, active infections, hematologic malignancies, or recent radiotherapy. The study aims to identify whether LGL levels are a simple blood-based marker associated with outcomes on PD-1 blockade.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological and staging diagnosis of metastatic non-small cell lung cancer
* ECOG performance score between 0 and 2
* No contraindications for nivolumab

Exclusion Criteria:

* Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy
* Those with a second primary malignancy undergoing active treatment
* Those who have not signed the informed consent form
* Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome
* Those who have undergone palliative or curative radiotherapy within the last three months
* Those with active viral/bacterial infections before nivolumab treatment
* Patients who have used steroids in the last three months

Where it's running

• Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
  Konya, Meram, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Ahmet Oruç MD
• Email: mdahmetoruc@gmail.com
• Phone: +90 0505 704 50 20

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• Bexmarilimab plus nivolumab in solid tumors, melanoma, and NSCLC

  This trial tests whether adding bexmarilimab to nivolumab can help people with melanoma, non-small cell lung cancer, or other advanced solid tumors whose cancer stopped responding to immune therapy.

  Recruiting at 2 sites Phase 1/2 Institute of Cancer Research, United Kingdom · Manchester and 1 other locations · NCT07718243

• Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer

  This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).

  Recruiting Phase 3 Akeso · Phoenix, Arizona and 24 other locations · NCT07700979

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• XTX501 in people with metastatic NSCLC and advanced solid tumors

  A first-in-human study tests XTX501, a PD-1/masked IL-2 drug, to see if it is safe and tolerable in people with metastatic NSCLC and selected advanced solid tumors.

  Recruiting at 3 sites Phase 1/2 Xilio Development, Inc. · Canton, Ohio and 2 other locations · NCT07688577

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.